The aim of our study was to selectively analyze newly diagnosed patients with acute myeloid leukemia treated with a hypomethylating agent and establish their risk for developing invasive fungal infections (IFIs). We stratified patients into concern for IFI versus no concern, and observed that patients of the male gender and those with underlying chronic obstructive pulmonary disease are at higher risk for concern for IFI, which may prompt clinicians to consider anti-mold prophylaxis in this setting.
Bibliographical noteFunding Information:
JS Blachly reports a consulting/advisory role for AstraZeneca and Kite Pharma; travel/accommodations/expense from Oxford Nanopore Technologies; patents: a sequencing technology patent pending; and honoraria from LifeSci Venture Partners. AR Walker reports travel/accommodations/expense from Gilead Sciences; and research funding from Gilead Science s. AS Mims reports a consulting/advisory role for Astellas Pharma, Agios, PTC Therapeutics, Jazz Pharmaceuticals, Abbvie/Genentech, Syndax Pharmaceuticals, and Kura Oncology, Inc. The remaining authors have stated that they have no conflicts of interest.
Research reported in this publication was supported by the Division of Hematology and Infectious Disease at The Ohio State University and James Comprehensive Cancer Center , with all authors listed above as assisting in the critical appraisal of its scientific work and writing of this manuscript. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
- Acute myeloid leukemia
- Anti-mold azoles
- Antifungal prophylaxis
- Risk stratification
PubMed: MeSH publication types
- Journal Article